NanoVibronix Announces Renewal and Expansion of Distribution Agreement with Dukehill Healthcare Pty Ltd in Australia

Rhea-AI Summary

NanoVibronix (NASDAQ: NAOV) has renewed and expanded its exclusive three-year distribution agreement with Dukehill Healthcare for its UroShield device across all Australian States. The agreement, previously focused on Queensland and New South Wales, now extends to South Australia and Victoria following increased healthcare facility inquiries.

The expansion comes after the publication of an independent study highlighting UroShield's effectiveness in reducing catheter-associated complications and improving patient outcomes. Dukehill will showcase UroShield at the 33rd National Conference on Incontinence in Hobart in May 2025, where clinicians will discuss the study findings.

Positive

• Expansion of distribution agreement to all Australian States
• Independent study validates UroShield's effectiveness
• Increasing inquiries and orders from healthcare facilities

Negative

• None.

Insights

Medical Device Market Analyst

NanoVibronix's expanded distribution agreement with Dukehill Healthcare represents a strategic market penetration opportunity in Australia. The transition from a regional to national distribution model across all Australian states signals growing market acceptance for their UroShield technology.

The catalyst behind this expansion appears to be twofold: increasing facility demand and the publication of an independent study validating UroShield's efficacy in reducing catheter-associated complications. This clinical validation is particularly significant in the medical device sector, where evidence-based adoption drives purchasing decisions.

The timing is opportune as catheter-associated urinary tract infections (CAUTIs) remain a major healthcare burden. Facilities increasingly seek non-pharmaceutical interventions to reduce these complications, and UroShield's acoustic wave technology addresses this need without additional pharmacological risks.

The three-year exclusive agreement provides NanoVibronix with stable market presence and recurring revenue potential. For context, the Australian urinary catheter market represents a valuable segment within the $4.5 billion global catheter market.

While financial terms weren't disclosed, this expanded distribution should positively impact NanoVibronix's revenue streams through increased geographic penetration and heightened clinical awareness following the independent study publication.

Publication of Independent Study Heightens Demand for UroShield

ELMSFORD, N.Y.--(BUSINESS WIRE)-- NanoVibronix, Inc. (NASDAQ: NAOV) (the “Company” or “NanoVibronix”), a medical technology company specializing in non-invasive therapeutic devices, today announced the renewal and expansion of its exclusive three-year distribution agreement with Dukehill Healthcare Pty Ltd. (“Dukehill”).

Dukehill, with its Head Office in Queensland, has primarily focused its clinical projects and sales efforts within the state and in New South Wales. However, the recent expansion of the agreement with the Company now extends across all Australian States, with notable growth in South Australia and Victoria. This surge follows an increasing number of inquiries and orders from healthcare facilities in these States. Additionally, the recent publication of an independent study in which researchers cited compelling findings that demonstrate UroShield’s effectiveness in reducing catheter-associated complications and enhancing patient outcomes, is expected to further drive sales across Australia.

Brian Murphy, Chief Executive Officer of NanoVibronix, commented, “We believe the renewal of our distribution partnership with Dukehill underscores the growing recognition of UroShield’s effectiveness in improving patient care and our dedication to making this technology more widely accessible. With Dukehill’s expanded presence in Australia and the heightened awareness generated by the recent study, we are confident in UroShield’s continued success in the market. This agreement with Dukehill is expected to enable more patients and healthcare providers to experience the benefits of our innovative technology.”

Toni Hill, Director of Dukehill, commented, “We are excited to strengthen our partnership with NanoVibronix and bring UroShield to a wider population across Australia. The growing interest in UroShield, combined with the positive study results, underscores the device’s potential to transform the management of urinary catheters and improve quality of life for patients.”

In addition to broadening its distribution, Dukehill will showcase the benefits of UroShield at the upcoming 33rd National Conference on Incontinence, hosted by Continence Health Australia, in Hobart in May 2025. Clinicians from across Australia are expected to meet and be able to discuss findings from the study as part of the conference program and exhibition, further reinforcing the device’s clinical efficacy and patient benefits. For information about the conference, please visit https://www.continence.org.au/NCOI.

About NanoVibronix, Inc.

NanoVibronix, Inc. (NASDAQ: NAOV) is a medical device company headquartered in Tyler, Texas, with research and development in Nesher, Israel, focused on developing medical devices utilizing its patented low intensity surface acoustic wave (SAW) technology. The proprietary technology allows for the creation of low-frequency ultrasound waves that can be utilized for a variety of medical applications, including for disruption of biofilms and bacterial colonization, as well as for pain relief. The devices can be administered at home without the continuous assistance of medical professionals. The Company’s primary products include PainShield® and UroShield®, which are portable devices suitable for administration at home or in any care setting. Additional information about NanoVibronix is available at: www.nanovibronix.com.

Forward-looking Statements

This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with: (i) market acceptance of our existing and new products or lengthy product delays in key markets; (ii) negative or unreliable clinical trial results; (iii) inability to secure regulatory approvals for the sale of our products; (iv) intense competition in the medical device industry from much larger, multinational companies; (v) product liability claims; (vi) product malfunctions; (vii) our limited manufacturing capabilities and reliance on subcontractor assistance; (viii) insufficient or inadequate reimbursements by governmental and/or other third party payers for our products; (ix) our ability to successfully obtain and maintain intellectual property protection covering our products; (x) legislative or regulatory reform impacting the healthcare system in the U.S. or in foreign jurisdictions; (xi) our reliance on single suppliers for certain product components; (xii) the need to raise additional capital to meet our future business requirements and obligations, given the fact that such capital may not be available, or may be costly, dilutive or difficult to obtain; (xiii) our conducting business in foreign jurisdictions exposing us to additional challenges, such as foreign currency exchange rate fluctuations, logistical and communications challenges, the burden and cost of compliance with foreign laws, and political and/or economic instabilities in specific jurisdictions; and (xiv) market and other conditions. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at: http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events, or otherwise, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250401951497/en/

Brett Maas, Managing Principal, Hayden IR, LLC

brett@haydenir.com

(646) 536-7331

Source: NanoVibronix, Inc.

FAQ

What is the duration and scope of NanoVibronix's new distribution agreement with Dukehill Healthcare?

The agreement is an exclusive three-year distribution deal covering all Australian States, expanded from the previous focus on Queensland and New South Wales.

How has the recent independent study affected NAOV's UroShield distribution in Australia?

The study demonstrated UroShield's effectiveness in reducing catheter complications, leading to increased inquiries and orders from healthcare facilities across Australia.

Where will Dukehill showcase NAOV's UroShield device in 2025?

UroShield will be showcased at the 33rd National Conference on Incontinence in Hobart, May 2025.

Which new Australian regions are included in NAOV's expanded distribution agreement?

The agreement now includes South Australia and Victoria, in addition to the previous regions of Queensland and New South Wales.